Alexion Skids as Muscle Drug Trial Fails to Meet Primary Goal

  • Shares fall the most since 2010 as results disappoint
  • Drug for muscle disease didn’t lead to activity improvements

Alexion Pharmaceuticals Inc. fell the most in six years after the company’s drug for a rare neuromuscular disease failed to meet its primary goal in a final-stage trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.